Compare Ascendis Pharma A/S (ASND) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Genuine Parts Company — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Genuine Parts Company trades at $135.22 (market cap $18.55B). The key difference: Ascendis Pharma A/S and Genuine Parts Company are close in size by market cap, and Genuine Parts Company pays a 3.16% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GPC | |
|---|---|---|
Market Cap | $16.78B | $18.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $149.26 |
52-Week Low | $189.74 | $92.47 |
Enterprise Value | $17.15B | $24.64B |
Dividend Yield | — | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
GPC trades at $135.63, up 2.14% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The stock is supported by strong Q2 2026 earnings beats, with sales growth of 6% year-over-year and an adjusted EPS of $2.15 beating estimates. However, net income margin remains thin at 0.13% for 2025, and the P/E ratio is elevated at 542.52, indicating high valuation relative to earnings. Recent news highlights institutional buying interest and reaffirmed 2026 adjusted EPS guidance of $7.50 to $8.00.
The outlook for GPC is cautiously optimistic, with analyst consensus pointing to a $148.67 price target and a 'Buy' rating from 43% of covering analysts. Key opportunities include sustained industrial segment strength and dividend consistency, while risks involve margin pressure from inflation, high debt levels, and competitive pressures in the auto parts industry. Earnings growth and cost management are critical for future stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
